Navigation Links
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Date:10/3/2007

Three Subcutaneous Doses of Ustekinumab Resulted in Long-term PASI 75 Response and Marked Improvement in Quality of Life Measures According to

Study Findings

BUENOS AIRES, Argentina, Oct. 3 /PRNewswire/ -- The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75). Importantly, findings also showed that following one additional dose at week 16, a substantial proportion of patients receiving ustekinumab maintained a PASI 75 response through week 28. Data from the study, presented at the World Congress of Dermatology, involved more than 1,200 subjects and showed that within four weeks of initiating treatment with ustekinumab, patients experienced significant and clinically meaningful improvements in quality of life measures compared with patients receiving placebo. Ustekinumab is a new, fully-human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), and is currently in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis.

These data, presented at the 21st meeting of the World Congress of Dermatology, will be the subject of a live press briefing and webcast (http://www.cnto1275wcd.com) today at 2 p.m. EDT featuring Craig Leonardi, MD, St. Louis University Medical School, St. Louis, MO, Kristian Reich, MD, Georg- August-University, Gottingen, Germany, Silvia Fernandez Barrio, executive director, Civil Association of Psoriasis Patients of Argentina, Buenos Aires, Argentina, and Tom Schaible, PhD, vice president, Medical Affairs, Centocor, Inc.

<
'/>"/>
SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... BARCELONA , October 31, 2014 ... to infringe two Australian patents of B. Braun Melsungen AG ... Australia safety IV catheters manufactured by Poly ... of Australia proceeding number VID 463 ... In the detailed judgment, Multigate was found to ...
(Date:10/31/2014)... , October 30, 2014 ... announced the addition of the  "Process Validation in ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... and Risk Based Approach to Process Validation for ... Management FDA Process Validation Guidance ...
(Date:10/31/2014)... , Oct. 31, 2014 Though therapies ... technologies are expected to show an annual increase of ... value of nearly $1 billion, according to Kalorama Information,s ... from proprietary stem cell therapeutics that have gained or ... "As drug developers tackle ever more complicated ...
Breaking Medicine Technology:B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Report: Stem Cell Technologies Market Growing 2
... May 11, 2012  Amgen (NASDAQ: AMGN ) ... vice president of Research and Development at Amgen will ... Administration (FDA) stakeholder hearing on biosimilars. Miletich will urge members ... for biosimilars to establish approval standards that advance patient ...
... Mylan Inc. (Nasdaq: MYL ) today ... mg, 20 mg, 40 mg and 80 mg in ... has received marketing authorization from each country,s respective health ... is the generic version of Pfizer,s Lipitor® Tablets. This ...
Cached Medicine Technology:Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 2Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 3Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 4Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 5Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 6Mylan Launches Generic Lipitor® in Five European Countries 2
(Date:10/31/2014)... This Method to get a ... for practitioners. , The Hypopresive (aka Hipopressive) ... and Movement specializing in physical rehabilitation. Dr. Marcel ... reeducation that traditional abdominal exercises after pregnancy increased ... etc. , The Hipopressives exercises pull back in ...
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Surgery for low back ... in the United States you live, a new report ... low back pain at some point in their lives, ... medical care for a spine problem," co-author Brook Martin, ... Practice, said in a college news release. In ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... 2014 Urban Hydroponics, Inc. (OTCQB:URHY), a ... it has signed a Binding Letter of Intent (LOI) ... cultivation sector - Urban Cultivator Inc. (“Urban Cultivator”), BC ... Metal Inc. (“W3 Metal” and together with Urban Cultivator ... to the LOI and an earlier non-binding term sheet, ...
(Date:10/31/2014)... October 31, 2014 Triple Board Certified ... hair restoration services to transform the appearance of military ... American Academy of Facial Plastic and Reconstruction Surgery (AAFPRS) ... to restore the facial hair Jones lost during an ... The pro-bono hair restoration procedure, valued around $16,000, took ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
... ... tracking, performance analysis, sales and management training, announced that its non-profit organization, PrideAmerica is ... Super Bowl Hearing Mission on Wednesday, February 3rd, from noon – 4 pm at ... ...
... NASHVILLE, Tenn. , Jan. 29 HCA ... quarter and fiscal year ended December 31, 2009 . ... Company,s year-end financial and accounting procedures. , (Logo: ... these uncertain economic times," said Richard M. Bracken , ...
... , DETROIT , Jan. 29 ... M.D., Ph.D., has been named the new president and chief ... thoracic oncologist, Dr. Bepler will begin his new position ... , In addition to his chief administrative duties, Dr. ...
... , CHICAGO , Jan. 29 ... decision, four national organizations representing dentists, physicians and veterinarians ... exclude health professionals from controversial new regulation intended to ... A letter sent to FTC Chairman Jon Leibowitz ...
... facial recognition systems, study authors suggest , FRIDAY, Jan. 29 ... as long as they think the faces are odd-shaped flowers, ... researchers from Australia and France determined that bees could be ... a sweet treat for doing so. , However, this doesn,t ...
... counterfeit Viagra, study says , FRIDAY, Jan. 29 (HealthDay ... especially drugs purporting to treat erectile dysfunction, are playing Russian ... best the drugs won,t help you and at worst they ... be wasting your money or you may actually be hurting ...
Cached Medicine News:Health News:CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission 2Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 2Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 3Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 4Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 5Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 6Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 7Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 8Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 3Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 4Health News:Health Professionals Petition FTC For Relief From Red Flags Rule 2Health News:Health Professionals Petition FTC For Relief From Red Flags Rule 3Health News:Fake Drugs Bought on the Web Pose Big Health Risks 2Health News:Fake Drugs Bought on the Web Pose Big Health Risks 3
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
Medicine Products: